title: The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome.
abstract: Sinusoidal dilatation found in the absence of an impaired sinusoidal blood outflow has been so far of unclear significance. Sinusoidal dilatation may actually be a nonspecific feature of impaired portal venous blood inflow, whatever the cause, or a feature of severe systemic inflammatory reaction syndrome, whatever the cause. Sinusoidal dilatation is mainly located in the centrilobular area even in the absence of an outflow block. A predominantly periportal location is specifically found in oral contraceptive users, associated with an inflammatory condition. There is strong evidence for the association of sinusoidal dilatation and oxaliplatin-based chemotherapy but not for estroprogestative steroids or thiopurine derivatives. Exposure to anabolic androgen steroids appears to cause sinusoidal changes different from a mere sinusoidal dilatation.
  
  
  CONCLUSIONS
  There is evidence of activation of the interleukin-6 and vascular endothelial growth factor pathways in sinusoidal dilatation, but the mechanisms linking the activation of these pathways with the microvascular changes must be identified.
authors: Dipartimento di Medicina Clinica, UOC di Gastroenterologia, Umberto I Policlinico di Roma, Sapienza Università di Roma, Rome, Italy.
authors: Chiara
authors: C
authors: Marzano
authors: DHU UNITY, Laboratoire Central d'Anatomie et de Cytologie Pathologiques, Hôpital Beaujon, HUPNVS, APHP, Clichy-la-Garenne, France.|DHU Unity, Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France.|CRI Paris-Montmartre, UMR 1149, Université Paris Diderot, PRES SPC, Hôpital Bichat, Paris, France.
authors: Dominique
authors: D
authors: Cazals-Hatem
authors: DHU Unity, Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France.|Inserm, U970, Paris Cardiovascular Research Center-PARCC, Université Paris Descartes, Sorbonne Paris Cité, UMR-S970, Paris, France.
authors: Pierre-Emmanuel
authors: PE
authors: Rautou
authors: DHU Unity, Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France.|CRI Paris-Montmartre, UMR 1149, Université Paris Diderot, PRES SPC, Hôpital Bichat, Paris, France.|Inserm U1149, Hôpital Bichat, Paris, France.
authors: Dominique-Charles
authors: DC
authors: Valla
mesh_terms: D000818:Animals; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D006975:Hypertension, Portal / Q000503:physiopathology; D015850:Interleukin-6 / Q000378:metabolism; D008102:Liver Circulation / Q000502:physiology; D008297:Male; D051379:Mice; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011168:Portal System / Q000503:physiopathology*; D011379:Prognosis; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D018746:Systemic Inflammatory Response Syndrome / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015850:Interleukin-6; D009944:Organoplatinum Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; C431073:oxiplatin